Mehmet Sinan DAL, Didem GÜRBÜZ GÖKÇEN, Özlem AKGÜN KINIK, İrfan TURSUN, Fatih BORLU, Fatma PAKSOY, Adile ÇAKIR, Turgay ULAŞ

Demir eksikliği anemili hastalarda intravenöz demir tedavisinin total antioksidan kapasite üzerine etkisi

Amaç: Parenteral demir tedavisi oral yolla alınan demirin emiliminin bozuk olduğu ya da oral demir tedavisine rağmen aneminin düzelmediği hastalarda tercih edilir. Parenteral demir tedavisinin etkinliği kanıtlanmıştır ancak yan etkileri ve uzun dönem kullanımında toksisite gelişimi üzerine dikkat çekilmektedir. Biz de bu çalışmada, intravenöz demir tedavisinin akut antioksidan kapasite ölçümü üzerine etkisini araştırdık. Gereç ve yöntem: Çalışmaya demir eksikliği anemisi olan 36 hasta ve 20 sağlıklı kontrol dahil edildi. İntravenöz demir tedavisi verilmeden önce hastalardan bazal total antioksidan kapasite düzeyi ölçümü için kan örnekleri alındı. Hastalara 100 mg demir sükroz intravenöz yolla bir saatte verildi. İnfüzyon bitiminden bir saat sonra hastalardan ilaç sonrası total antioksidan kapasiteyi değerlendirmek üzere tekrar kan alındı. Bulgular: Demir eksikliği anemisi olan grupta tedavi öncesi total antioksidan kapasite düzeyi (280±34 μmol/L) kontrol grubuna (365±58 μmol/L) göre anlamlı olarak düşük tespit edildi (p=0.001). Tedavi sonrasında ise total antioksidan kapasite düzeyinde (264±35 μmol/L) anlamlı düşüş görüldü (p=0.01). Hastaların hiçbirinde intravenöz demir sukroz uygulanmasına bağlı yan etki görülmedi. Sonuç: Bu çalışmada, demir eksikliği anemisinin ve tedavisinde kullanılan intravenöz demir preparatının oksidatif stresi arttırdığı görüldü. Klin Deney Ar Derg 2011; 2 (3): 287-291.

The effect of intravenous iron therapy on total antioxidant capacity in patients with iron deficiency anemia

Objectives: Parenteral iron is used for patients who are either unable to absorb oral iron or who have increasing anemia despite adequate doses of per oral iron. Parenteral iron preparations are clearly effective, but concerns have been raised regarding adverse events and potentially long-term toxicity. So, in this study we aimed to investigate the effect of intravenous iron therapy on acute antioxidant capacity. Materials and methods: Totally 36 patients with iron deficiency anemia and 20 healthy controls were included in the study. Prior to iron infusion to subjects, blood samples were obtained for measurement of total antioxidant capacity. Then patients received 100 mg intravenous iron sucrose in an hour. And at the first hour after the infusion was completed, the blood samples were repeated. Results: Before the treatment total antioxidant capacity was significantly lower in anemic patients (280±34 μmol/L) than in control group (365±58 μmol/L) (p=0.001). Significantly decreased total antioxidant capacity (264±35 μmol/L) was found after the iron treatment (p=0.01). No adverse events related to intravenous iron were observed. Conclusion: In this study, we observed that intravenously administered iron sucrose in 100 mg dose and also iron deficiency anemia itself, caused increased oxidative stress. J Clin Exp Invest 2011; 2 (3): 287-291.

PDF

___

1. Öztürk A, Özkan Y, Sezer M, Kandemir G, Başak M, Üskent N. [Iron deficiency anemia: three-year results of us.] GATA Bülteni 1997;39: 204-7.
2. Dilek İ, Altun S, Tuncer İ, Uygan İ, Topal C, Aksoy H. [Hemoglobin, hematocrit levels, erythrocyte indexes and evaluation of etiological causes in iron deficiency anemia.] Van Tıp Dergisi 2000;7(2): 51-6.
3. Yılmaz K, Kahraman A, Bodur S, Koçar S, Köken T. [Reduced glutathione and antioxidant enzyme activities in erythrocytes of patients with iron-deficiency anemia.] Türkiye Klinikleri J Med Sci 2004;24(4): 305-8.
4. Aslan M, Horoz M, Kocyigit A, et al. Lymphocyte DNA damage and oxidative stress in patients with iron deficiency anemia. Mutat Res 2006;601(1-2): 144-9.
5. Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol 2000;53(1 Suppl): 18-22.
6. Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol 2006;1 Suppl 1: 24-31.
7. Çavdar C, Temiz A, Yeniçerioğlu Y, et al. [The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients the effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.] Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 2001;10(2): 77-82.
8. Hanimoglu H, Tanriverdi T, Kacira T, et al. Relationship between DNA damage and total antioxidant capacity in patients with transitional meningioma. Clin Neurol Neurosurg 2007;109(7): 561-6.
9. Plit ML, Theron AJ, Fickl H, van Rensburg CE, Pendel S, Anderson R. Influence of antimicrobial chemotherapy and smoking status on the plasma concentrations of vitamin C, vitamin E, beta-carotene, acute phase reactants, iron and lipid peroxides in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 1998;2(7): 590-6.
10. Güler T, Çelebi N, Sürer H, et al. [Serum total antioxidant status in pulmonary tuberculosis patients]. Türkiye Klinikleri J Med Sci 2004;24(6): 618-23.
11. Herrera J, Nava M, Romero F, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001;37(4): 750-7.
12. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000;11(3): 539-49.
13. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002;40(5): 1005-12.
14. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65(6): 2279-89.
15. Cavdar C, Camsari T, Semin I, Gönenc S, Acikgöz O. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol 1997;31(4): 371-5.
16. Bayes B, Sierra C, Pastor MC, Bonal J. Effect of intravenous iron therapy on oxidative stress in hemodialysis. Nephrol Dial Transplant 1998;13(6): A 206.
17. Kumerova A, Lece A, Skesters A, Silova A, Petuhovs V. Anaemia and antioxidant defence of the red blood cells. Mater Med Pol 1998;30(1-2): 12-5.
18. Vives Corrons JL, Miguel-García A, Pujades MA, et al. Increased susceptibility of microcytic red blood cells to in vitro oxidative stress. Eur J Haematol 1995;55(5): 327-31.
19. Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr 1986;6: 13-40.
20. Knutson MD, Walter PB, Ames BN, Viteri FE. Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. J Nutr 2000;130(3): 621-8.
21. Sevgi Y, Gönenç C, Ciğdem A. Neutrophil glutathione peroxidase activity in iron deficiency anaemia. Scand J Haematol 1986;36(1): 58-60.
22. Cellerino R, Guidi G, Perona G. Plasma iron and erythrocytic glutathione peroxidase activity. A possible mechanism for oxidative haemolysis in iron deficiency anemia. Scand J Haematol 1976;17(2): 111-6.
23. Isler M, Delibas N, Guclu M, et al. Superoxide dismutase and glutathione peroxidase in erythrocytes of patients with iron deficiency anemia: effects of different treatment modalities. Croat Med J 2002;43(1): 16-9.